Inhaled Lipid Cisplatin(Eleison Pharma)

顺铂脂质体吸入剂

Report date: 2025/09/12 14:00:34

Base Information

Drug NameInhaled Lipid Cisplatin(Eleison Pharma)
Drug Alias Namecisplatine氯氨铂cisplatino顺-二氯二氨络铂Cisplatinum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA cross linking agentsDNA synthesis inhibitors
TargetsDNA
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEleison Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesEleison Pharmaceuticals Llc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG